drugset / Trial / NCT03752970

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

NCT03752970 ↗

Phase 2 Completed 27 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas. In this part of the study, tissue samples are taken from patients. The second part of the study tests whether a medicine called spesolimab (BI 655130) helps patients with Crohn's Disease. Participants get study medication for 24 weeks. The participants are put into 2 groups. It is decided by chance who gets into which group. One group gets an intravenous drip that contains spesolimab every 4 weeks. The other group gets a placebo drip every 4 weeks. The placebo drip looks like the spesolimab drip, but contains no medicine. The doctors regularly examine fistulas of the participants. The results of the fistula examinations are compared between the groups. The doctors also check the general health of the patients.

Timeline

Start
2019-02-05
Primary completion
2021-12-01
Completion
2022-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Spesolimab Monoclonal antibody 1200 mg Intravenous

Indications